Phase 1/2a Trial of T3011 Oncolytic HSV with IL-12 and PD-1 Ab in Advanced Solid Tumors

Overview

This first-in-human phase 1/2a study evaluated T3011, an oncolytic herpes simplex virus engineered to express IL-12 and anti-PD-1 antibody, administered intratumorally in patients with advanced solid tumors including recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The trial demonstrated a favorable safety profile and preliminary evidence of anti-tumor activity, supporting further clinical development.

Background

T3011 is designed to selectively infect and lyse tumor cells while inducing a systemic anti-tumor immune response via localized expression of IL-12 and anti-PD-1 antibody. IL-12 is a pro-inflammatory cytokine critical for enhancing immune checkpoint inhibitor efficacy but is limited by systemic toxicity when administered systemically. Head and neck squamous cell carcinomas (HNSCC) represent a heterogeneous group of tumors with poor prognosis in recurrent/metastatic settings despite recent advances with immune checkpoint inhibitors. Local intratumoral delivery of T3011 aims to maximize anti-tumor immunity while minimizing systemic adverse effects.

Data Highlights

The study included dose-escalation phases with doses ranging from 2.5 × 10⁵ to 1 × 10⁸ PFU/mL, followed by an expansion phase at the recommended phase 2 dose (RP2D). Safety was assessed over a 28-day dose-limiting toxicity (DLT) evaluation period, with follow-up for survival every 3 months up to 2 years. Patients enrolled had advanced or metastatic solid tumors including sarcomas, head and neck cancers, breast cancer, and melanoma.

Key Findings

• T3011 demonstrated a manageable safety profile with no unexpected toxicities during dose escalation and expansion phases.
• Intratumoral administration achieved localized expression of IL-12 and anti-PD-1 antibody, potentially enhancing anti-tumor immune responses within the tumor microenvironment.
• Preclinical data supported superior oncolytic activity and immune activation compared to systemic administration of IL-12 and PD-1 antibody alone.
• Preliminary efficacy signals were observed in patients with recurrent or metastatic HNSCC, a population with limited treatment options and poor prognosis.
• Localized expression of PD-1 inhibitor may overcome limited tumor penetration and reduce immune-related adverse events compared to systemic checkpoint blockade.

Clinical Implications

The intratumoral delivery of T3011 offers a novel therapeutic strategy to enhance anti-tumor immunity in advanced solid tumors, particularly in recurrent/metastatic HNSCC where current treatments are suboptimal. By confining IL-12 and PD-1 antibody expression to the tumor site, T3011 may improve efficacy while minimizing systemic toxicity, supporting its further clinical evaluation as monotherapy or in combination regimens.

Conclusion

T3011 represents a promising oncolytic viral immunotherapy that leverages localized cytokine and checkpoint inhibitor expression to stimulate robust anti-tumor responses with an acceptable safety profile. These phase 1/2a results warrant continued investigation in larger trials to confirm clinical benefit in advanced solid tumors including HNSCC.

Related Resources & Content

1. 1 -- Engineering of T3011 Oncolytic Virus
2. 2 -- IL-12 and Immune Checkpoint Inhibitors in Cancer Therapy
3. 3,4 -- IL-12 Role in T Cell Differentiation
4. 5 -- Activation of T and NK Cells by IL-12
5. 6 -- IL-12 Effects on Regulatory T Cells
6. 7 -- IL-12 Requirement for Anti-PD-1 Therapy
7. 8 -- IL-12 and IL-2 Overcoming ICI Resistance
8. 9-14 -- Clinical Context of HNSCC and Immunotherapy
9. 15 -- Preclinical Validation of T3011
10. 16,17 -- Intranodal Injection for Immune Activation
11. 18,19 -- Oncolytic Virus-Mediated Checkpoint Inhibitor Expression